<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107339</url>
  </required_header>
  <id_info>
    <org_study_id>EH14-113</org_study_id>
    <nct_id>NCT02107339</nct_id>
  </id_info>
  <brief_title>Methadone and Hydromorphone For Spinal Surgery</brief_title>
  <official_title>Methadone and Hydromorphone For Spinal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthShore University HealthSystem Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NorthShore University HealthSystem Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing major spinal surgery continue to experience moderate-to-severe pain
      during the first 2-3 days following the operative procedure. Pain complicates the recovery
      process, despite the routine practice of using potent opioid analgesics. The primary reason
      that pain is poorly controlled in patients undergoing major surgery is that most
      commonly-used opioids only produce analgesia for 2-4 hours. The intermittent use of these
      drugs results in periods of time when a patient will experience discomfort (at which time a
      nurse administers more drug or the button on a patient-controlled analgesic (PCA) system is
      pressed to deliver more medication). The use of a long-acting opioid may be advantageous in
      the perioperative setting. Methadone is an opioid that has a median duration of analgesia of
      24-36 hours. Therefore, a single dose administered in the operating room may reduce the need
      for pain medication and improve pain control for the first few postoperative days. The aim of
      this randomized clinical trial is to examine the effect of methadone (compared to
      hydromorphone) on postoperative pain management in patients undergoing major spine surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients: 100 patients (ages 18-80) will be enrolled in this clinical trial. All patients
      presenting for elective posterior lumbar or thoracic spinal fusion surgery will be eligible
      for enrollment. Patients will be randomized to receive either methadone or hydromorphone on
      the basis of a computer generated random number table. Patients in each group will receive
      standard clinical intraoperative doses of either methadone (0.2 mg/kg) or hydromorphone (2
      mg). An analysis of patients undergoing posterior lumbar fusion surgery at Evanston Hospital
      revealed that patients received, on average, approximately 2 mg of hydromorphone
      intraoperatively. The most commonly used doses of methadone administered in clinical studies
      have been either 0.2 mg/kg or a dose of 20 mg. Furthermore, these doses also represent
      dosages which appear to be approximately equipotent. Study medications will be prepared by
      the pharmacy, and all clinicians will be blinded to group assignment. Two syringes will be
      prepared for each patient, one which contains the study drug (either methadone 0.2 mg/kg or
      hydromorphone 2 mg), and the other containing the placebo (saline). If the patient is
      randomized to the methadone group, a 3 cc syringe containing 0.2 mg/kg of methadone and
      saline (total volume 3 cc) will be prepared, as well as a 10 cc syringe containing 10 cc of
      saline (placebo). If the patient is randomized to the hydromorphone group, a 3 cc syringe
      containing 3 cc of saline (placebo) will be prepared, as well as a 10 cc syringe containing 2
      mg of hydromorphone with 9 cc of saline (total volume 10 cc). At induction of anesthesia, the
      3 cc syringe containing either 0.2 mg/kg of methadone or placebo will be given over 5
      seconds. At the conclusion of surgery, the 10 cc syringe of either hydromorphone or placebo
      will be titrated slowly per clinician's preference. The administration of all other
      anesthetic agents will be standardized and reflect the usual practices of anesthesiologists
      at Evanston Hospital (spine protocol).

      Anesthesia will be standardized and include propofol for induction, a propofol and
      remifentanil infusion for maintenance (plus sevoflurane), and IV acetaminophen 1000 mg during
      the last 60 minutes of the case.

      On arrival to the postanesthesia care unit (PACU), patients will be assessed for pain by PACU
      nurses per standard protocols. Patients will be evaluated for pain on PACU arrival and then
      every 15 minutes. Patients will be administered hydromorphone 0.25-0.5 mg for pain, and doses
      will be repeated until the patient is comfortable (pain &lt; 3 on a scale of 0-10; 0=no pain and
      10=worst pain imaginable). The patient will then be connected to a PCA device to deliver pain
      medication during the remainder of the postoperative period.

      All postoperative management will be per standard surgical protocols

      Sample Size: The primary end-point of the investigation is amount of hydromorphone used. In a
      clinical trial by Urban et al. of patients undergoing complex spine surgery using a standard
      anesthetic, average hydromorphone consumption in the first 24 hours was 27 mg (18). The
      investigators expect to see at least a 33% reduction in hydromorphone consumption in the
      methadone group. Group sample sizes of 39 and 39 achieve 91% power to detect a difference of
      9.0 between the null hypothesis that both group means are 27.0 and the alternative hypothesis
      that the mean of group 2 is 18.0 with estimated group standard deviations of 10.0 and 10.0
      and with a significance level (alpha) of 0.01000 using a two-sided two-sample t-test. The
      investigators plan to enroll a total of 100 patients to ensure complete collection of data.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hydromorphone Use at 24 Hours</measure>
    <time_frame>Use of hydromorphone at 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hydromorphone Use Second 24 Hours</measure>
    <time_frame>24-48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hydromorphone Use Third 24 Hours</measure>
    <time_frame>48-72 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores Postanesthesia Care Unit (PACU) Arrival</measure>
    <time_frame>First 5 minutes after PACU arrival</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores 1 Hour After PACU Arrival</measure>
    <time_frame>Pain scores at 60 minutes after PACU admission</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores 2 Hours After PACU Arrival</measure>
    <time_frame>Pain scores at 120 minutes after PACU admission</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on Postoperative Day One</measure>
    <time_frame>Pain scores one day after PACU admission</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on Postoperative Day 2</measure>
    <time_frame>Pain scores 48 hours after PACU admission</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores Postoperative Day 3</measure>
    <time_frame>Pain scores 72 hours after PACU admission</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Scores</measure>
    <time_frame>Postopertive day 1</time_frame>
    <description>Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Scores</measure>
    <time_frame>postoperative day 2</time_frame>
    <description>Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Scores</measure>
    <time_frame>Postoperative day 3</time_frame>
    <description>Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Persistent Surgical Pain</measure>
    <time_frame>One month after surgery</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Persistent Surgical Pain</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Persistent Surgical Pain</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Persistent Surgical Pain</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hydromorphone Use</condition>
  <condition>Acute Postoperative Pain</condition>
  <condition>Patient Satisfaction</condition>
  <condition>Chronic Persistent Surgical Pain</condition>
  <arm_group>
    <arm_group_label>methadone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydromorphone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>Methadone 0.2 mg/kg administered at induction of anesthesia</description>
    <arm_group_label>methadone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
    <arm_group_label>Hydromorphone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting for elective posterior lumbar or thoracic spinal fusion
             surgery will be eligible for enrollment.

        Exclusion Criteria:

          1. Preoperative renal failure (defined as a serum creatinine &gt; 2.0 mg/dL.)

          2. American Society of Anesthesiologists Physical Status IV or V

          3. Pulmonary disease necessitating home oxygen therapy

          4. Allergy to methadone or hydromorphone

          5. Preoperative recent history of opioid or alcohol abuse

          6. Inability to use a PCA device or speak the English language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn S Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <results_first_submitted>July 7, 2016</results_first_submitted>
  <results_first_submitted_qc>July 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2016</results_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NorthShore University HealthSystem Research Institute</investigator_affiliation>
    <investigator_full_name>Glenn S. Murphy, MD</investigator_full_name>
    <investigator_title>Director, Clinical Research</investigator_title>
  </responsible_party>
  <keyword>methadone</keyword>
  <keyword>hydromorphone</keyword>
  <keyword>acute postoperative pain</keyword>
  <keyword>chronic persistent surgical pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Methadone Group</title>
          <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
        </group>
        <group group_id="P2">
          <title>Hydromorphone Group</title>
          <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methadone Group</title>
          <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
        </group>
        <group group_id="B2">
          <title>Hydromorphone Group</title>
          <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" lower_limit="57" upper_limit="71"/>
                    <measurement group_id="B2" value="60" lower_limit="45" upper_limit="66"/>
                    <measurement group_id="B3" value="62" lower_limit="48" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hydromorphone Use at 24 Hours</title>
        <time_frame>Use of hydromorphone at 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Hydromorphone Use at 24 Hours</title>
          <units>milligrams</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" lower_limit="2.3" upper_limit="7.1"/>
                    <measurement group_id="O2" value="9.9" lower_limit="6.45" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hydromorphone Use Second 24 Hours</title>
        <time_frame>24-48 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Hydromorphone Use Second 24 Hours</title>
          <units>milligrams</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0" upper_limit="2.8"/>
                    <measurement group_id="O2" value="3.15" lower_limit="0.75" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hydromorphone Use Third 24 Hours</title>
        <time_frame>48-72 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Hydromorphone Use Third 24 Hours</title>
          <units>milligrams</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.35" lower_limit="0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores Postanesthesia Care Unit (PACU) Arrival</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>First 5 minutes after PACU arrival</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores Postanesthesia Care Unit (PACU) Arrival</title>
          <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores 1 Hour After PACU Arrival</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>Pain scores at 60 minutes after PACU admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores 1 Hour After PACU Arrival</title>
          <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores 2 Hours After PACU Arrival</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>Pain scores at 120 minutes after PACU admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores 2 Hours After PACU Arrival</title>
          <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores on Postoperative Day One</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>Pain scores one day after PACU admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores on Postoperative Day One</title>
          <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores on Postoperative Day 2</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>Pain scores 48 hours after PACU admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores on Postoperative Day 2</title>
          <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="6" lower_limit="3.5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores Postoperative Day 3</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>Pain scores 72 hours after PACU admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores Postoperative Day 3</title>
          <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Scores</title>
        <description>Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))</description>
        <time_frame>Postopertive day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction Scores</title>
          <description>Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="85" upper_limit="100"/>
                    <measurement group_id="O2" value="80" lower_limit="70" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Scores</title>
        <description>Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))</description>
        <time_frame>postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction Scores</title>
          <description>Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="85" upper_limit="100"/>
                    <measurement group_id="O2" value="82.5" lower_limit="70" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Scores</title>
        <description>Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))</description>
        <time_frame>Postoperative day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone Group</title>
            <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone Group</title>
            <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction Scores</title>
          <description>Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="90" lower_limit="77.5" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Persistent Surgical Pain</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>One month after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Persistent Surgical Pain</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>3 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Persistent Surgical Pain</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>6 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Persistent Surgical Pain</title>
        <description>11-point verbal rating scale (0=no pain, 10=worst pain imaginable)</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>two weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Methadone Group</title>
          <description>Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia</description>
        </group>
        <group group_id="E2">
          <title>Hydromorphone Group</title>
          <description>Patients will receive hydromorphone 2 mg at the end of the surgical procedure
Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Glenn Murphy</name_or_title>
      <organization>NorthShore University HealthSystem</organization>
      <phone>847-570-2760</phone>
      <email>dgmurphy2@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

